Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Cantor Fitzgerald
Deloitte
Johnson and Johnson
Teva
AstraZeneca
Argus Health
UBS

Generated: June 21, 2018

DrugPatentWatch Database Preview

Pierre Fabre Company Profile

« Back to Dashboard

What is the competitive landscape for PIERRE FABRE, and what generic alternatives to PIERRE FABRE drugs are available?

PIERRE FABRE has three approved drugs.

There is one US patent protecting PIERRE FABRE drugs.

There are thirty-eight patent family members on PIERRE FABRE drugs in thirty countries.

Summary for Pierre Fabre
International Patents:38
US Patents:1
Tradenames:3
Ingredients:3
NDAs:3
Patent Litigation for Pierre Fabre: See patent lawsuits for Pierre Fabre

Drugs and US Patents for Pierre Fabre

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre NAVELBINE vinorelbine tartrate INJECTABLE;INJECTION 020388-001 Dec 23, 1994 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes 8,338,489 ➤ Sign Up ➤ Sign Up
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Pierre Fabre ETOPOSIDE etoposide INJECTABLE;INJECTION 074813-001 Jul 9, 1997 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Pierre Fabre

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Sign Up
9,173,858 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Citi
Fuji
Covington
Argus Health
UBS
Farmers Insurance
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.